RNA Q2 2025 Earnings — Avidity Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RNAAvidity Biosciences, Inc.

$2B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+88.1% YoY

Gross Profit

-$134M-3490.5% margin

Operating Income

-$171M-4448.7% margin

Net Income

-$157M-4089.3% margin

EPS (Diluted)

$-1.21

QoQ Revenue Growth

+144.6%

Cash Flow

Operating Cash Flow

-$200M

Free Cash Flow

-$203M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$176M

Stockholders' Equity

$1.2B

Cash & Equivalents

$244M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$2M	+88.1%
Gross Profit	-$134M	$1M	-9987.9%
Operating Income	-$171M	-$83M	-107.1%
Net Income	-$157M	-$71M	-122.2%

Revenue Segments

Reportable Segment

$4M100%